Twist Bioscience Corporation (TWST) Reports Q4 Loss of $6.59; Offers FY19 Revenue Guidance

Twist Bioscience Corporation (NASDAQ: TWST) reported Q4 EPS of ($6.59), versus ($6.68) reported last year. Revenue for the quarter came in at $8.4 million, versus $3.5 million reported last year.

“It has been an exceptional year for Twist Bioscience, with significant top-line growth across all business areas and both operational and commercial accomplishments,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “We’ve doubled our revenue coming from our synthetic biology products, launched our target enrichment kits for next-generation sequencing, which is gaining traction in the marketplace, expanded internationally, and laid a foundation for both our drug discovery and DNA digital data storage verticals. In addition, we strengthened our balance sheet with the closing of both a private financing and our initial public offering.

“Looking ahead into fiscal 2019, we expect to continue to deliver on our mission to improve healthcare and sustainability through synthetic DNA as we expand our customer base, convert pilot customers to production, grow revenue across all product categories and geographic regions, as well as validate our GPCR and antibody optimization software for Twist Biopharma and pursue non-dilutive financing for digital data storage.”

GUIDANCE:

Twist Bioscience Corporation sees FY2019 revenue of $46-48 million.

For earnings history and earnings-related data on Twist Bioscience Corporation (TWST) click here.

You May Also Be Interested In

• Plexus Corp (PLXS) Tops Q2 EPS by 7c
• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• Nanometrics (NANO) Issues Business Update, Reports FY23 Results